←
DCVC Bio933 posts
DCVC Bio avatar

DCVC Bio

@DCVCBio

Venture Capital investing in companies solving big life science problems with deep tech

◷ Joined December 2017▧ 16 Photos and videos
DCVC Bio avatar
DCVC Bio@DCVCBio·30 Sep 2024

We're proud to announce DCVC Bio III: $400 million in fresh capital to support great scientific teams with boundary-pushing ideas for curing disease, extending health-spans, enabling healthy food at lower cost and climate impact, and more! bit.ly/3ZRmdpo

DCVC avatar
⟳ DCVC Bio retweeted
DCVC@DCVC·Oct 30

A look at what @DCVC /@DCVCBio founders delivered /this week/: 💪 🚚 🤖 Fleet-scale humanoid deployment: @agilityrobotics expanded its commercial footprint with GXO Logistics, soon moving into facilities across North Carolina and Tennessee after crossing an unprecedented 100,000-tote operational milestone. ⚛️ Microreactor regulatory progress: @RadiantNuclear cleared a major hurdle as the US Dep't of @ENERGY approved the documented safety analysis for its Kaleidos test unit at @INL, moving it one step closer to criticality. 🧬 Predictive computational biology: Latus Bio published the first predictive computational model of Huntington’s disease built on human data in Nature Communications, along with preclinical data supporting its gene therapy candidate LTS-201 as a potentially disease-modifying treatment. This is BIG. 🔬 Rapid stem cell reprogramming: @SyntaxBio drew major biotech coverage for using its CRISPR-based Cellgorithm platform to differentiate human stem cells into pancreatic beta cells in just four days, an early step toward faster development of cell therapies for Type 1 diabetes. 🎯 Clinical precision oncology: @FrontierMeds posted a standout 56% confirmed response rate in its Phase 1 lung cancer trial (FMC-376) presented at the ESMO - European Society for Medical Oncology Congress. 💡 Quantum photonics breakthrough: @NVisionQuantum published research introducing the first organic molecule capable of directly linking quantum processors with light, unlocking a scalable path for optical quantum networking. 🧠 Frontier AI compute architecture: Unconventional AI (@unconvAI) AI CEO @NaveenGRao joined @20vcFund to talk about why inference could be a $10 trillion market and why robotics could be 100x bigger than coding agents. Onward!

Post attachment
DCVC Bio avatar
DCVC Bio@DCVCBio·Sep 14

Drug discovery has always started with sick patients. @DCVCBio-backed @alchemabtx flips that—sequencing the immune systems of people who carry disease-causing mutations but never get sick, then using AI to turn those signals into life-saving drugs. Read more below 🧵

Post attachment
DCVC Bio avatar
DCVC Bio@DCVCBio·Jun 10

Great piece from @FierceBiotech on how @UnlearnAI is using digital twins to transform clinical trial decision-making 👇 fiercebiotech.com/sponsored/…

DCVC Bio avatar
DCVC Bio@DCVCBio·Jun 9

Exciting progress for Syntax Bio: a research and development collaboration with @MayoClinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes 👏 businesswire.com/news/home/2…

BiotechTV avatar
⟳ DCVC Bio retweeted
BiotechTV@BiotechTV·May 7

𝐂𝐨𝐧𝐯𝐞𝐫𝐠𝐞𝐧𝐜𝐞 𝐅𝐨𝐫𝐮𝐦: Chicago based Grove Biopharma has engineered a technology, Bionic Biologics, that it hopes will give its therapies the versatility of biologics in a small molecule format. #ConvergenceForum

6:15
Jesse Landry avatar
⟳ DCVC Bio retweeted
Jesse Landry@JesseDLandry·May 6

Gene therapy is moving from promise to precision. Latus Bio added a $43M Series A extension from @8vc, @DCVCBio, and Hatch BioFund, bringing the round to $97M. P. Peter Ghoroghchian is building an AI-enabled platform focused on precision AAV delivery for neurological disease. The next biotech edge will come from pairing better vectors with better computational judgment.

DCVC Bio avatar
DCVC Bio@DCVCBio·Mar 30

At @DCVCBio, we see a need for a massive rein­vest­ment in the search for drugs that safely lessen anxiety, including existing compounds that have been shelved by big pharma companies. More on our thinking in 🧵

Post attachment
DCVC Bio avatar
DCVC Bio@DCVCBio·Mar 16

RNA- and DNA-based treatments (gene/cell therapy) have high upfront costs but are curative and more economical than chronic care. Regulators should work with insurers and manufacturers to cover costs and introduce new business models, like gradual payment plans. More in 🧵

Post attachment
DCVC Bio avatar
DCVC Bio@DCVCBio·Mar 10

We’re seeing a new wave of gene therapy companies developing exquisitely customized viral vectors + other advanced techniques that can deliver therapeutic genes to the body with far more specificity and at much lower doses and cost than before. 👇 dcvc.com/news-insights/deep-…

Post attachment